Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was still reeling Monday, a day ahead of its meeting with the FDA's Oncologic Drugs Advisory Committee. Hitting an all-time record for the Newton, Mass.-based company, nearly 16.6 million shares were traded Friday when the FDA released its briefing materials for the meeting, raising concerns that Karyopharm's lead agent, selinexor, wouldn't get support for accelerated approval to treat refractory multiple myeloma.